NI-1801
MSLN-positive solid tumors (e.g., PROC)
Phase IIActive
Key Facts
Indication
MSLN-positive solid tumors (e.g., PROC)
Phase
Phase II
Status
Active
Company
About Light Chain Bioscience
Light Chain Bioscience is a private, clinical-stage biotech advancing a pipeline of bispecific antibodies using its proprietary Kλ body technology. Its lead programs target CD47 in a tumor-restricted manner to overcome historical safety challenges, with one asset in Phase II and several others in Phase I/II development. The company operates a partnership-driven business model, co-developing assets with partners like LamKap Bio, and is positioned in the competitive but high-potential bispecific antibody and CD47-targeting therapeutic space.
View full company profile